Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?

Genome medicine - 25 Oct 2016

O'Donnell Jake S, Smyth Mark J, Teng Michele W L

Abstract excerpt

Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recent study sought to identify mutations associated with resistance to anti-PD1 therapy. Results from this study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to B7-H1 Antigen
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Programmed Cell Death 1 Receptor

Share to T-Lymphocytes

Source

Open in PubMed Open full text

Identifiers

PMID: 27782862
DOI: 10.1186/s13073-016-0365-1
PMCID: PMC5080691

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?PMID 27782862Read ↗

Phenotypic Plasticity, Non-genetic Mechanisms, and Immune Drug Resistance in Cancer.Semantic proximity Read ↗

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.Semantic proximity Read ↗

Mechanism of resistance to immune checkpoint inhibitorsSemantic proximity Read ↗

De-novo and acquired resistance to immune checkpoint targetingSemantic proximity Read ↗

Unmasking PD-1 Resistance by Next-Generation SequencingSemantic proximity Read ↗

Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and <i>MET</i> amplificationSemantic proximity Read ↗

Molecular patterns of resistance to immune checkpoint blockade in melanomaSemantic proximity Read ↗

Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeSemantic proximity Read ↗

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.Semantic proximity Read ↗

Mechanisms of Acquired Resistance to Targeted Cancer TherapiesSemantic proximity Read ↗

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.Semantic proximity Read ↗

New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunitiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.